This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Arrow Electronics, Clipper Realty, Pfizer, BioNTech and Moderna highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Arrow Electronics, Clipper Realty, Pfizer, BioNTech and Moderna highlighted as Zacks Bull and Bear of the Day
Vaccine Hopes Rise as Pharma Giants Inch Closer Toward Success
by Ritujay Ghosh
Stocks of Eli Lilly and Company (LLY), Pfizer, Inc. (PFE) and Moderna, Inc. (MRNA) have been in focus since the coronavirus outbreak as they have been the frontrunners in the vaccine race.
Vaccine News Lifts Energy Stocks Higher: 5 Stocks to Watch
by Zacks Equity Research
COVID-19 vaccine news aid energy stocks in moving higher making it judicious to watch out for prominent names like Oasis Petroleum (OASPQ) and PDC Energy (PDCE)
Vaccine Hopes Drive Demand for Value Stocks: 5 Picks
by Tirthankar Chakraborty
Value stocks are in favor now on vaccine hopes, which calls for investing in Red Robin Gourmet Burgers (RRGB), Matson (MATX), Malibu Boats (MBUU), Farmers National Banc (FMNB) and Northrim BanCorp (NRIM).
Vaccine Hopes & Divided Government: Sector ETFs to Win
by Sanghamitra Saha
News that a Pfizer and BioNTech vaccine candidate was more than 90% effective in avoiding COVID-19 in its clinical trial has instilled more optimism in the markets.
Airline Stocks Gain on Vaccine News: Is the Rally Sustainable?
by Maharathi Basu
Shares of Delta (DAL), American Airlines (AAL) and United Airlines (UAL) appreciate in double-digits on Nov 9. Improvement in leisure-travel demand also bodes well for the airline stocks.
BioNTech's (BNTX) Q3 Loss Wider-Than Expected, Revenues Beat
by Zacks Equity Research
BioNTech (BNTX) miss estimates for earnings in the third quarter of 2020 while revenues beat the same.
Stock Market News for Nov 10, 2020
by Zacks Equity Research
Wall Street ended mostly higher on Monday as investor confidence got a boost after data from late-stage clinical trials of coronavirus vaccine from two drugmakers showed positive results.
Pfizer COVID-19 Vaccine Data Raises Hopes for Industry, Economy
by Kinjel Shah
Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate proves to be 90% effective in phase III.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Mohawk Industries, Electrolux and Jabil
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Mohawk Industries, Electrolux and Jabil
Zacks Investment Ideas feature highlights: Pfizer, BioNTech, Delta Air Lines, Disney and Peloton Interactive
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Pfizer, BioNTech, Delta Air Lines, Disney and Peloton Interactive
4 Top-Ranked Energy Stocks to Scoop Up Post Monday's Rally
by Nilanjan Choudhury
DCP Midstream (DCP), Abraxas Petroleum (AXAS), Matador Resources (MTDR) and NuStar (NS) were up more than 10% yesterday with more gains ahead on a potential coronavirus treatment and revival in oil demand.
5 Blue-Chip Stocks to Buy on Coronavirus Vaccine Hope
by Nalak Das
A COVID-19 vaccine likely to benefit the Dow the most as it is more inclined toward cyclical stocks. Five among these are NIKE (NKE), Dow (DOW), The Procter & Gamble (PG), 3M (MMM) and Microsoft (MSFT).
5 ETFs Up Double Digits in a Day on Vaccine Optimism
by Sanghamitra Saha
Wall Street soared on Nov 9 on news that Pfizer (PFE) and BioNTech (BNTX) vaccine candidate was more than 90% effective in avoiding COVID-19 in its clinical trial.
2 Stocks to Watch on Pfizer's 90% Effective COVID-19 Vaccine
by Tirthankar Chakraborty
Pfizer's (PFE) shares hit an all-time high during yesterday's trading session on its milestone COVID-19 vaccine news, while Moderna's (MRNA) soared on optimism as it applies a similar technology.
More Foot-Traffic & Less Click-Traffic
by Daniel Laboe
Yesterday's hopeful vaccine news from Pfizer (PFE) and BioNTech (BNTX) has put a light at the end of the tunnel for value investors
Markets Rejoice Pfizer (PFE) Vaccine News
by Mark Vickery
For the month of November thus far, the Dow has already climbed more than 10%.
The Sea Looks Calm: Global Week Ahead
by John Blank
This is not going to be an interesting week, relative to last week's exhausting line-up of major events. ??????That's OK with me. I expect it is OK with you, too.
Positive News on COVID-19 Vaccine
by Zacks Equity Research
Positive News on COVID-19 Vaccine
Pfizer's Covid Drug Proves 90%+ Effective; PFE, BNTX
by Mark Vickery
A Covid vaccine takes the lid off most everything market-related. That said, we're still looking at a period of months before it would be widely available.
Why Earnings Season Could Be Great for BioNTech (BNTX)
by Zacks Equity Research
BioNTech (BNTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What A Vaccine Means For The Stock Market
by Daniel Laboe
The markets are pricing in the end of the pandemic. This means more foot traffic and less click traffic.
Can Coronavirus Vaccine Efforts Aid BioNTech (BNTX) Q3 Earnings?
by Zacks Equity Research
On BioNTech's (BNTX) upcoming Q3 earnings call, investors' focus will be on the progress and advancement of its COVID-19 vaccine candidate, currently being developed in partnership with Pfizer.
What's in Store for AstraZeneca (AZN) This Earnings Season?
by Zacks Equity Research
AstraZeneca's (AZN) third-quarter results are expected to reflect the impact of new drug sales.
5 Drug/Biotech Stocks Set to Outpace Q3 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.